Lomedeucitinib vs Nomelcitinib (D-2570)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Lomedeucitinib

Developed by Beeline Medicines under a licence from Bristol-Myers Squibb

Phase 2 in Psoriasissmall molecule
Partial signal

NCT05730725 · Phase 2 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.

Reported efficacy

Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)

Result source: NCT05730725

Nomelcitinib (D-2570)

Developed by InventisBio

Phase 3 in PsoriasisSmall molecule (oral TYK2 JH2 pseudokinase-domain inhibitor)
Partial signal

NCT06278350 · Phase 2 · completed

The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.

Next expected readout: July 2027 · NCT07326813 (registry estimate)

Reported efficacy

Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)

Result source: NCT06278350

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLomedeucitinibNomelcitinib (D-2570)
PASI 7563% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07130604
PASI 9040.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07130604
PASI 1003.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07130604
sPGA 0/155.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
—Trial running · NCT07130604
DLQI, change—Not reported—Trial running · NCT07130604

PASI 75

Lomedeucitinib
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 90

Lomedeucitinib
40.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 100

Lomedeucitinib
3.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
Nomelcitinib (D-2570)
—Trial running · NCT07130604

sPGA 0/1

Lomedeucitinib
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
Nomelcitinib (D-2570)
—Trial running · NCT07130604

DLQI, change

Lomedeucitinib
—Not reported
Nomelcitinib (D-2570)
—Trial running · NCT07130604
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Nomelcitinib (D-2570)
Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) NCT06278350 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lomedeucitinib: 3 of 4 rows · Nomelcitinib (D-2570): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLomedeucitinib
Dropout rate
7.4%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
3.7%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
—BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
—BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
0%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
acne 14.8% (placebo 0%)
covid-19 11.1% (placebo 0%)
dermatitis acneiform 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
aphthous ulcer 11.1% (placebo 0%)
folliculitis 11.1% (placebo 0%)
upper respiratory tract infection 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
diarrhoea 7.4% (placebo 0%)
headache 7.4% (placebo 0%)
influenza 7.4% (placebo 3.6%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lomedeucitinib

PASI 75 63% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
57.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
72% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
11.5% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
33.3% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
47.8% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.4% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
40% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
sPGA 0/1 55.6% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
69.2% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.2% (n=24) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 50 81.5% (n=27) vs 17.9% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
65.4% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
88.5% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=26) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
34.6% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
85.2% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
73.9% (n=23) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
14.8% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48.1% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
84% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
81.8% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 90 40.7% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
18.5% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
25.9% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13.6% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 100 3.7% (n=27) vs 0% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=26) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=23) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -3.36 vs -0.5 placebo score @ 1wk
absolute change · score
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 14 more results
-6.27 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.05 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.06 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.44 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.95 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.13 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.63 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.66 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.39 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.85 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.16 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.53 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.34 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.55 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lomedeucitinib's landscape · Nomelcitinib (D-2570)'s landscape